THE WHAT? Costco has entered into an settlement with Novo Nordisk to promote the drugmaker’s GLP-1 drugs Ozempic and Wegovy at roughly 50% beneath their normal retail value. The supply is obtainable to Costco members via its prescription program for US$499 per four-week provide.
THE DETAILS The partnership allows Costco to offer reputable, manufacturer-sourced GLP-1 weight-loss drugs amid a market setting dominated by inflated costs and counterfeit options. The discounted supply applies solely to members paying out of pocket, as most U.S. well being insurers nonetheless don’t cowl anti-obesity therapies. Each Ozempic and Wegovy include semaglutide, a GLP-1 analogue that mimics a pure hormone regulating urge for food and insulin response. Novo Nordisk presently fills greater than 200,000 Wegovy prescriptions weekly within the U.S., however provide constraints and the rise of unapproved compounded variations have sophisticated the market. Costco’s entry may improve entry to reputable provide whereas intensifying pricing stress on rivals and compounders.
THE WHY? The transfer underscores each Costco’s rising affect in healthcare retail and the continuing shopper demand for GLP-1-based weight-loss therapies. For Novo Nordisk, the collaboration strengthens management over distribution and helps fight the proliferation of unauthorized formulations amid hovering demand and restricted insurance coverage protection.
Supply: The Guardian
